$49.46
−0.10%Aug 18, 2026, 14:23 UTC
GSK announced that Canada's drug agency issued a positive reimbursement recommendation for NUCALA (mepolizumab) for the treatment of chronic obstructive pulmonary disease in adults.
Source:Aug 18, 2026, 02:38 UTC
Chugai Pharmaceutical and GlaxoSmithKline signed an exclusive license agreement on August 18, 2026, granting GSK global rights to develop, manufacture, and commercialize the dengue antibody drug AID351, with Chugai eligible for royalties and a share of sublicensing revenue.
Source:Aug 17, 2026, 22:00 UTC
The UK government announced on August 12 that it is investing 22 million pounds, including 20 million pounds for a new Pre-clinical Translational Models Hub in Cambridge, to grow miniature human organs from NHS patients' cells for drug testing.
Source:Jul 22, 2026, 17:58 UTC
The US FDA approved GSK's Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor.
Jul 17, 2026, 00:00 UTC
GSK discontinues development of camlipixant, an experimental chronic cough medicine, after mixed Phase 3 data.
Jul 14, 2026, 13:31 UTC
GSK announces positive interim phase II data for its drug Jemperli in rectal cancer, meeting the primary endpoint and supporting potential regulatory filings.
Source:Jun 24, 2026, 19:36 UTC
Nuvalent, Inc. agreed to be acquired by GSK plc for $124.00 per share in cash.
Jun 17, 2026, 16:36 UTC
The US FDA approved Utebzi (tebipenem pivoxil), an oral antibiotic developed by GSK and Spero Therapeutics, for adults with complicated urinary tract infections in the US.
Jun 12, 2026, 14:56 UTC
GSK's momelotinib received orphan drug designation from the FDA and EMA for VEXAS syndrome.
Source:Jun 8, 2026, 10:16 UTC
Engitix entered a strategic collaboration with GSK to advance first-in-class targets for liver fibrosis regression using Engitix's human ECM platform.
Source:
← PreviousPage 2